Sarcosine
•Last Updated: September 28 2022
Sarcosine is a product of glycine. It can be used as a cognitive enhancer and to treat schizophrenia.
Sarcosine is most often used for
Last Updated: September 28 2022
Sarcosine, also known as N-methylglycine, is a metabolite of glycine. It shares properties with both glycine and D-serine, though its effects are weaker.
Sarcosine supplementation can be used to alleviate symptoms of depression and schizophrenia, or improve cognition. It is absorbed more reliably by the body than D-serine, which can also treat similar conditions.
Sarcosine is being investigated for its connection to prostate cancer. It may be a biomarker for prostate cancer, which means that if sarcosine levels in the blood are higher than normal, it could be an indicator of prostate cancer. This doesn’t mean that sarcosine itself causes cancer. More research is needed to confirm this relationship.
Sarcosine’s main mechanism involves inhibiting a transporter, called GlyT1, which takes up glycine and D-serine into cells. This increases the levels of glycine and D-serine in the body and increases their effects.
It is unknown at this time if sarcosine supplementation is harmful. It may act as a co-carcinogen, meaning it doesn’t cause cancer, but increases the effects of other cancer-causing compounds.
The standard sarcosine dose is 30mg/kg of bodyweight, which correlates to an approximate dosage range of 2,045 – 2,727mg for people between 150 – 200 lbs.
Sarcosine is taken daily.
1.^Yeo EJ, Wagner CTissue distribution of glycine N-methyltransferase, a major folate-binding protein of liverProc Natl Acad Sci U S A.(1994 Jan 4)
3.^Porter DH, Cook RJ, Wagner CEnzymatic properties of dimethylglycine dehydrogenase and sarcosine dehydrogenase from rat liverArch Biochem Biophys.(1985 Dec)
4.^Dodt G, Kim DG, Reimann SA, Reuber BE, McCabe K, Gould SJ, Mihalik SJL-Pipecolic acid oxidase, a human enzyme essential for the degradation of L-pipecolic acid, is most similar to the monomeric sarcosine oxidasesBiochem J.(2000 Feb 1)
5.^Bergeron F, Otto A, Blache P, Day R, Denoroy L, Brandsch R, Bataille DMolecular cloning and tissue distribution of rat sarcosine dehydrogenaseEur J Biochem.(1998 Nov 1)
6.^Wang YC, Tang FY, Chen SY, Chen YM, Chiang EPGlycine-N methyltransferase expression in HepG2 cells is involved in methyl group homeostasis by regulating transmethylation kinetics and DNA methylationJ Nutr.(2011 May)
7.^Cook RJ, Wagner CGlycine N-methyltransferase is a folate binding protein of rat liver cytosolProc Natl Acad Sci U S A.(1984 Jun)
8.^Heady JE, Kerr SJPurification and characterization of glycine N-methyltransferaseJ Biol Chem.(1973 Jan 10)
9.^Rowling MJ, McMullen MH, Chipman DC, Schalinske KLHepatic glycine N-methyltransferase is up-regulated by excess dietary methionine in ratsJ Nutr.(2002 Sep)
10.^Meyer TE, Fox SD, Issaq HJ, Xu X, Chu LW, Veenstra TD, Hsing AWA reproducible and high-throughput HPLC/MS method to separate sarcosine from α- and β-alanine and to quantify sarcosine in human serum and urineAnal Chem.(2011 Jul 15)
11.^Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, Lein M, Jung KSarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumoursEur Urol.(2010 Jul)
12.^Gray JA, Roth BLThe pipeline and future of drug development in schizophreniaMol Psychiatry.(2007 Oct)
13.^Zhang HX, Hyrc K, Thio LLThe glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycineJ Physiol.(2009 Jul 1)
14.^McBain CJ, Kleckner NW, Wyrick S, Dingledine RStructural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytesMol Pharmacol.(1989 Oct)
15.^Rabe CS, Tabakoff BGlycine site-directed agonists reverse the actions of ethanol at the N-methyl-D-aspartate receptorMol Pharmacol.(1990 Dec)
16.^Zorumski CF, Thio LL, Clark GD, Clifford DBCalcium influx through N-methyl-D-aspartate channels activates a potassium current in postnatal rat hippocampal neuronsNeurosci Lett.(1989 May 8)
17.^Isaacson JS, Murphy GJGlutamate-mediated extrasynaptic inhibition: direct coupling of NMDA receptors to Ca(2+)-activated K+ channelsNeuron.(2001 Sep 27)
18.^Eulenburg V, Armsen W, Betz H, Gomeza JGlycine transporters: essential regulators of neurotransmissionTrends Biochem Sci.(2005 Jun)
19.^López-Corcuera B, Martínez-Maza R, Núñez E, Roux M, Supplisson S, Aragón CDifferential properties of two stably expressed brain-specific glycine transportersJ Neurochem.(1998 Nov)
20.^Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJPharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomesNeuropharmacology.(2001 Jul)
21.^Mallorga PJ, Williams JB, Jacobson M, Marques R, Chaudhary A, Conn PJ, Pettibone DJ, Sur CPharmacology and expression analysis of glycine transporter GlyT1 with {3H}-(N-{3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl})sarcosineNeuropharmacology.(2003 Oct)
22.^Zhang HX, Lyons-Warren A, Thio LLThe glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonistNeuropharmacology.(2009 Oct-Nov)
23.^Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, Harris RB, Disterhoft JFGLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulatorNeuropharmacology.(2005 Dec)
24.^Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JF, Stanton PK, Moskal JRThe N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging ratsNeurobiol Aging.(2011 Apr)
25.^Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JTGene knockout of glycine transporter 1: characterization of the behavioral phenotypeProc Natl Acad Sci U S A.(2004 Jun 1)
26.^Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H, Boison DDisruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profileJ Neurosci.(2006 Mar 22)
27.^Shimazaki T, Kaku A, Chaki SD-Serine and a glycine transporter-1 inhibitor enhance social memory in ratsPsychopharmacology (Berl).(2010 Apr)
28.^Chan MH, Chung SS, Stoker AK, Markou A, Chen HHSarcosine attenuates toluene-induced motor incoordination, memory impairment, and hypothermia but not brain stimulation reward enhancement in miceToxicol Appl Pharmacol.(2012 Dec 1)
29.^Karasawa J, Hashimoto K, Chaki SD-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in ratsBehav Brain Res.(2008 Jan 10)
30.^Olney JW, Farber NBGlutamate receptor dysfunction and schizophreniaArch Gen Psychiatry.(1995 Dec)
31.^Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GGProgress towards validating the NMDA receptor hypofunction hypothesis of schizophreniaCurr Top Med Chem.(2006)
32.^Coyle JTThe glutamatergic dysfunction hypothesis for schizophreniaHarv Rev Psychiatry.(1996 Jan-Feb)
33.^Coyle JT, Tsai GThe NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophreniaPsychopharmacology (Berl).(2004 Jun)
35.^Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo MDecreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophreniaArch Gen Psychiatry.(2003 Jun)
36.^Hashimoto KGlycine transport inhibitors for the treatment of schizophreniaOpen Med Chem J.(2010 May 27)
37.^Bergeron R, Meyer TM, Coyle JT, Greene RWModulation of N-methyl-D-aspartate receptor function by glycine transportProc Natl Acad Sci U S A.(1998 Dec 22)
38.^Aragón C, López-Corcuera BGlycine transporters: crucial roles of pharmacological interest revealed by gene deletionTrends Pharmacol Sci.(2005 Jun)
39.^Borowsky B, Mezey E, Hoffman BJTwo glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common geneNeuron.(1993 May)
40.^Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RLCloning and expression of a glycine transporter reveal colocalization with NMDA receptorsNeuron.(1992 May)
41.^Zafra F, Gomeza J, Olivares L, Aragón C, Giménez CRegional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNSEur J Neurosci.(1995 Jun 1)
42.^Danysz W, Parsons CGGlycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applicationsPharmacol Rev.(1998 Dec)
43.^Zafra F, Aragón C, Giménez CMolecular biology of glycinergic neurotransmissionMol Neurobiol.(1997 Jun)
44.^Tsai G, Lane HY, Yang P, Chong MY, Lange NGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophreniaBiol Psychiatry.(2004 Mar 1)
45.^Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GESarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled studyArch Gen Psychiatry.(2005 Nov)
46.^Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GEA randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaInt J Neuropsychopharmacol.(2010 May)
47.^Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai GGlycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophreniaBiol Psychiatry.(2006 Sep 15)
48.^Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JTD-serine added to clozapine for the treatment of schizophreniaAm J Psychiatry.(1999 Nov)
49.^Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada MClozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytesBr J Pharmacol.(2012 Mar)
50.^Tsai G, Yang P, Chung LC, Lange N, Coyle JTD-serine added to antipsychotics for the treatment of schizophreniaBiol Psychiatry.(1998 Dec 1)
51.^Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein MEfficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophreniaArch Gen Psychiatry.(1999 Jan)
52.^Heresco-Levy U, Silipo G, Javitt DCGlycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophreniaPsychopharmacol Bull.(1996)
53.^van Berckel BN, Hijman R, van der Linden JA, Westenberg HG, van Ree JM, Kahn RSEfficacy and tolerance of D-cycloserine in drug-free schizophrenic patientsBiol Psychiatry.(1996 Dec 15)
54.^Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DCPlacebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophreniaAm J Psychiatry.(2002 Mar)
56.^Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, Tun R, Huang KH, Chang YC, Lane HY, Tsai GEInhibition of Glycine Transporter-I as a Novel Mechanism for the Treatment of DepressionBiol Psychiatry.(2013 Apr 2)
57.^Otte DM, Barcena de Arellano ML, Bilkei-Gorzo A, Albayram O, Imbeault S, Jeung H, Alferink J, Zimmer AEffects of Chronic D-Serine Elevation on Animal Models of Depression and Anxiety-Related BehaviorPLoS One.(2013 Jun 21)
58.^Yang FY, Lee YS, Cherng CG, Cheng LY, Chang WT, Chuang JY, Kao GS, Yu LD-cycloserine, sarcosine and D-serine diminish the expression of cocaine-induced conditioned place preferenceJ Psychopharmacol.(2013 Jun)
59.^Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AMMetabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature.(2009 Feb 12)
60.^Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AMThe role of sarcosine metabolism in prostate cancer progressionNeoplasia.(2013 May)
61.^Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, Bethan B, Kristiansen G, Jung KSarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progressionJ Urol.(2011 Feb)
62.^Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, Yao XDEfforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urineProstate Cancer Prostatic Dis.(2011 Jun)
63.^Cao DL, Ye DW, Zhang HL, Zhu Y, Wang YX, Yao XDA multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancerProstate.(2011 May 15)
64.^Bianchi F, Dugheri S, Musci M, Bonacchi A, Salvadori E, Arcangeli G, Cupelli V, Lanciotti M, Masieri L, Serni S, Carini M, Careri M, Mangia AFully automated solid-phase microextraction-fast gas chromatography-mass spectrometry method using a new ionic liquid column for high-throughput analysis of sarcosine and N-ethylglycine in human urine and urinary sedimentsAnal Chim Acta.(2011 Nov 30)
65.^Lucarelli G, Fanelli M, Larocca AM, Germinario CA, Rutigliano M, Vavallo A, Selvaggi FP, Bettocchi C, Battaglia M, Ditonno PSerum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/mlProstate.(2012 Nov)
66.^Bohm L, Serafin AM, Fernandez P, Van der Watt G, Bouic PJ, Harvey JPlasma sarcosine does not distinguish early and advanced stages of prostate cancerS Afr Med J.(2012 Jun 28)
67.^Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience.(1987 Jan 9)
68.^Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et alStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience.(1989 May 12)
69.^Shi Y, Brands FH, Chatterjee S, Feng AC, Groshen S, Schewe J, Lieskovsky G, Cote RJHer-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent diseaseJ Urol.(2001 Oct)
70.^Koumakpayi IH, Le Page C, Mes-Masson AM, Saad FHierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancerBr J Cancer.(2010 Mar 30)
71.^Dahl M, Bouchelouche P, Kramer-Marek G, Capala J, Nordling J, Bouchelouche KSarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cellsMol Biol Rep.(2011 Oct)
72.^Cernei N, Zitka O, Skalickova S, Gumulec J, Sztalmachova M, Rodrigo MA, Sochor J, Masarik M, Adam V, Hubalek J, Trnkova L, Kruseova J, Eckschlager T, Kizek REffect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell lineOncol Rep.(2013 Jun)
73.^Hoorn AJDimethylglycine and chemically related amines tested for mutagenicity under potential nitrosation conditionsMutat Res.(1989 Apr)
74.^Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarría MJThe tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levelsJ Biol Chem.(2011 May 6)
75.^Liu SP, Li YS, Chen YJ, Chiang EP, Li AF, Lee YH, Tsai TF, Hsiao M, Huang SF, Chen YMGlycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in the liverHepatology.(2007 Nov)
76.^Dizik M, Christman JK, Wainfan EAlterations in expression and methylation of specific genes in livers of rats fed a cancer promoting methyl-deficient dietCarcinogenesis.(1991 Jul)